🔴 Neumora Therapeutics is trading 6.22% down today after prior-session rebound; no fresh catalyst identified

Neumora Therapeutics is trading 6.22% lower at $0.73, with no new company-specific catalyst identified for September 23, 2026.

• The decline follows a 12.53% rebound to $0.78 on September 22; it suggests early-session selling after the bounce rather than a confirmed fresh announcement.
• Earlier navacaprant Phase 3 failures and a planned 35% workforce reduction remain background overhangs; both were announced previously.